Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse.
1. Twenty-one schizophrenic or schizoaffective patients with histories of cannabis abuse and operationally-defined syndromes of post-psychotic depression completed a double-blind trial of adjunctive imipramine added to their on-going medication regimen of fluphenazine decanoate and benztropine. 2. The imipramine-treated patients had superior global outcome. 3. Subscales suggested that specific improvement occurred in imipramine-treated patients in the domain of depression-like features. 4. Psychotic symptomatology was not found to be exacerbated by the imipramine.
Siris
S G
SG
Hillside Hospital Division of the Long Island Jewish Medical Center, Glen Oaks, New York.
Bermanzohn
P C
PC
Mason
S E
SE
Rifkin
A
A
Alvir
J M
JM
D000293:Adolescent; D000328:Adult; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D002189:Marijuana Abuse / Q000150:complications*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D007099:Imipramine